The global role of biotechnology for non communicable disorders

Serena Zacchigna; Mauro Giacca

doi:10.1016/j.jbiotec.2018.07.043

The global role of biotechnology for non communicable disorders

Serena Zacchigna^*, Mauro Giacca

^*Corresponding author for this work

Cardiovascular Medicine & Sciences

International Centre for Genetic Engineering and Biotechnology

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

The World Health Organization (WHO) has tagged non-communicable diseases (NCDs) as one of the twenty-first century's major development challenges. NCDs account for over 15 million deaths annually and over 80% of those deaths occur in developing countries and among the poorest populations. Biotechnology presents unique opportunities to improve the early diagnosis and the treatment of NCDs. This review describes the major applications of biotechnology for a better clinical management of NCDs, i.e. the implementation of innovative diagnostic approaches and the production of innovative treatments, including those based on monoclonal antibodies, recombinant proteins, regulatory nucleic acids and cell-based therapies for regenerative medicine. In this context, it also examines the major challenges faced by biotechnology in developing countries.

Original language	English
Pages (from-to)	115-119
Number of pages	5
Journal	JOURNAL OF BIOTECHNOLOGY
Volume	283
DOIs	https://doi.org/10.1016/j.jbiotec.2018.07.043
Publication status	Published - 10 Oct 2018

Keywords

Cell therapy
Diagnostics
Monoclonal antibodies
Non communicable disorders
Recombinant proteins
Small nuclei acids

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jbiotec.2018.07.043

Cite this

@article{b5968c0da5154c3fa58dd59caa22f124,

title = "The global role of biotechnology for non communicable disorders",

abstract = "The World Health Organization (WHO) has tagged non-communicable diseases (NCDs) as one of the twenty-first century's major development challenges. NCDs account for over 15 million deaths annually and over 80% of those deaths occur in developing countries and among the poorest populations. Biotechnology presents unique opportunities to improve the early diagnosis and the treatment of NCDs. This review describes the major applications of biotechnology for a better clinical management of NCDs, i.e. the implementation of innovative diagnostic approaches and the production of innovative treatments, including those based on monoclonal antibodies, recombinant proteins, regulatory nucleic acids and cell-based therapies for regenerative medicine. In this context, it also examines the major challenges faced by biotechnology in developing countries.",

keywords = "Cell therapy, Diagnostics, Monoclonal antibodies, Non communicable disorders, Recombinant proteins, Small nuclei acids",

author = "Serena Zacchigna and Mauro Giacca",

year = "2018",

month = oct,

day = "10",

doi = "10.1016/j.jbiotec.2018.07.043",

language = "English",

volume = "283",

pages = "115--119",

journal = "JOURNAL OF BIOTECHNOLOGY",

issn = "0168-1656",

publisher = "Elsevier",

}

TY - JOUR

T1 - The global role of biotechnology for non communicable disorders

AU - Zacchigna, Serena

AU - Giacca, Mauro

PY - 2018/10/10

Y1 - 2018/10/10

N2 - The World Health Organization (WHO) has tagged non-communicable diseases (NCDs) as one of the twenty-first century's major development challenges. NCDs account for over 15 million deaths annually and over 80% of those deaths occur in developing countries and among the poorest populations. Biotechnology presents unique opportunities to improve the early diagnosis and the treatment of NCDs. This review describes the major applications of biotechnology for a better clinical management of NCDs, i.e. the implementation of innovative diagnostic approaches and the production of innovative treatments, including those based on monoclonal antibodies, recombinant proteins, regulatory nucleic acids and cell-based therapies for regenerative medicine. In this context, it also examines the major challenges faced by biotechnology in developing countries.

AB - The World Health Organization (WHO) has tagged non-communicable diseases (NCDs) as one of the twenty-first century's major development challenges. NCDs account for over 15 million deaths annually and over 80% of those deaths occur in developing countries and among the poorest populations. Biotechnology presents unique opportunities to improve the early diagnosis and the treatment of NCDs. This review describes the major applications of biotechnology for a better clinical management of NCDs, i.e. the implementation of innovative diagnostic approaches and the production of innovative treatments, including those based on monoclonal antibodies, recombinant proteins, regulatory nucleic acids and cell-based therapies for regenerative medicine. In this context, it also examines the major challenges faced by biotechnology in developing countries.

KW - Cell therapy

KW - Diagnostics

KW - Monoclonal antibodies

KW - Non communicable disorders

KW - Recombinant proteins

KW - Small nuclei acids

UR - http://www.scopus.com/inward/record.url?scp=85051043429&partnerID=8YFLogxK

U2 - 10.1016/j.jbiotec.2018.07.043

DO - 10.1016/j.jbiotec.2018.07.043

M3 - Article

C2 - 30077584

AN - SCOPUS:85051043429

SN - 0168-1656

VL - 283

SP - 115

EP - 119

JO - JOURNAL OF BIOTECHNOLOGY

JF - JOURNAL OF BIOTECHNOLOGY

ER -

The global role of biotechnology for non communicable disorders

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this